| 32 | 1/1 | 返回列表 |
| 查看: 1549 | 回復(fù): 31 | |||
[交流]
色譜B投稿交流
|
|||
|
外審?fù)旰笈卸ù笮,各位幫我看看,有希望?br />
Comments: Dear Dr. Xueying, Thank you for submitting your manuscript to J. Chrom. B. Based on the received referee report I request a major revision of your manuscript. There are notably important parameters of your study that should be clarified according to current regulatory guidelines. Please address all comments and submit a revised version of your study for further review. Sincerely yours, Rainer Bischoff Editor in Chief Reviewer #1: The article is interesting and revision is required in improving the method development and validation as per USFDA JULY 2015 recommendation for method validation of drugs and biologic. Please find the queries as enlisted (i) Method robustness needs to be evaluated and discussed in method development (ii) Comparative and contrasting model of bio-distribution has not been cited . A reference model is required to be incorporated so that the study findings are anchored to the extant knowledge domain (iii) Need to provide statistical methods to confirm matrix effect in different lots have no impact on method. Statistical support as per USFDA JULY 2015 recommendation for method validation of drugs and biologic clearly states for such confirmatory analysis. (iv) Figures with T-joint to show there is no ion suppression or enhancement at the retention time of analyte is important and should be essentially discussed. (v) Metabolites monitoring needs to be discussed. (vi) Discussion on using ESI mode of mass spectrometry, employing liquid -liquid chromatography and reason for selecting Inertsil ®ODS3 C18 column for separation has not been clarified. (vii) Syntax errror and English usage needs to be improved throughout the paper. (viii) Authors should argue the potential of being a high-throughput method due to achieving separation from both endogenous and exogenous interfering compounds. (ix) Quality of method should be discussion with clarity against the reported literature. (x) However, considering the merit of the research highlights, the article has a potential to fit in short communication category after revision. Though the article couldn't be accepted in current form, it is suggested that authors work on the major points as discussed above and resubmit for consideration. Once again, thanking you for contributing in bio-distribution field and best wishes for your future endeavors. |
» 搶金幣啦!回帖就可以得到:
+5/785
+1/163
+1/95
+1/86
+1/74
+1/66
+1/61
+1/47
+1/39
+2/30
+1/30
+1/13
+1/10
+1/6
+3/5
+1/4
+1/3
+1/2
+1/2
+1/1
| 32 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 281求調(diào)劑(0805) +14 | 煙汐憶海 2026-03-16 | 25/1250 |
|
|---|---|---|---|---|
|
[考研] 295材料求調(diào)劑,一志愿武漢理工085601專碩 +4 | Charlieyq 2026-03-19 | 4/200 |
|
|
[考研] 0856調(diào)劑,是學校就去 +8 | sllhht 2026-03-19 | 9/450 |
|
|
[考研]
|
簡木ChuFront 2026-03-19 | 7/350 |
|
|
[考研] 274求調(diào)劑 +8 | S.H1 2026-03-18 | 8/400 |
|
|
[考研] 【考研調(diào)劑】化學專業(yè) 281分,一志愿四川大學,誠心求調(diào)劑 +6 | 吃吃吃才有意義 2026-03-19 | 6/300 |
|
|
[考博] 申博26年 +3 | 八6八68 2026-03-19 | 3/150 |
|
|
[考研] 288求調(diào)劑,一志愿華南理工大學071005 +5 | ioodiiij 2026-03-17 | 5/250 |
|
|
[考研] 0817調(diào)劑 +3 | 沒有答案_ 2026-03-14 | 3/150 |
|
|
[考研] 材料工程專碩調(diào)劑 +5 | 204818@lcx 2026-03-17 | 6/300 |
|
|
[考研] 一志愿華中科技大學,080502,354分求調(diào)劑 +4 | 守候夕陽CF 2026-03-18 | 4/200 |
|
|
[考研] 290求調(diào)劑 +3 | p asserby. 2026-03-15 | 4/200 |
|
|
[考研] 一志愿蘇州大學材料工程(085601)專碩有科研經(jīng)歷三項國獎兩個實用型專利一項省級立項 +6 | 大火山小火山 2026-03-16 | 8/400 |
|
|
[考博] 26申博 +4 | 八6八68 2026-03-16 | 4/200 |
|
|
[論文投稿] 有沒有大佬發(fā)小論文能帶我個二作 +3 | 增銳漏人 2026-03-17 | 4/200 |
|
|
[考研] 一志愿,福州大學材料專碩339分求調(diào)劑 +3 | 木子momo青爭 2026-03-15 | 3/150 |
|
|
[考研] 283求調(diào)劑 +3 | 聽風就是雨; 2026-03-16 | 3/150 |
|
|
[考研] 326求調(diào)劑 +4 | 諾貝爾化學獎覬?/a> 2026-03-15 | 7/350 |
|
|
[考研] 304求調(diào)劑 +3 | 曼殊2266 2026-03-14 | 3/150 |
|
|
[考研] 中科院材料273求調(diào)劑 +4 | yzydy 2026-03-15 | 4/200 |
|